MedTrace Logo

A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity

NCT07767175 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 142

Last updated 2026-08-17

No results posted yet for this study

Summary

The purpose of the study is to find out if NNC0721-8060 is safe and how it works in people living with overweight or obesity.

Conditions

Interventions

DRUG

NNC0721-8060

NNC0721-8060 will be administered subcutaneously.

DRUG

Semaglutide

Semaglutide will be administered subcutaneously.

DRUG

Placebo

Placebo will be administered subcutaneously.

Sponsors & Collaborators

Principal Investigators

  • Clinical Transparency (dept. 2834) · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-08-12
Primary Completion
2027-09-23
Completion
2027-09-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07767175 on ClinicalTrials.gov